Mouse LRIG1 Alexa Fluor® 750-conjugated Antibody

Catalog #: FAB3688S Datasheet

Catalog #	Availability	Size / Price	Qty
FAB3688S-100UG

All LRIG1 Antibodies

Product Details

FAQs

Supplemental Products

Reviews

Summary Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Mouse LRIG1 Alexa Fluor® 750-conjugated Antibody Summary

Species Reactivity

Mouse

Specificity

Detects mouse LRIG1 in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant human LRIG3 is observed.

Source

Monoclonal Rat IgG2a Clone # 440710

Purification

Protein A or G purified

Immunogen

Mouse myeloma cell line NS0-derived recombinant mouse LRIG1
Ala37-Thr794
Accession # P70193

Formulation

Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Label

Alexa Fluor 750 (Excitation= 749 nm, Emission= 775 nm)

Applications

Recommended Concentration

Sample

Blockade of Receptor-ligand Interaction

Optimal dilution of this antibody should be experimentally determined.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Preparation and Storage

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

Background: LRIG1

LRIG1 (formerly LIG-1) is one of three mammalian LRR (leucine-rich repeat) and Ig-like domain-containing type I transmembrane glycoproteins that share 45‑50% amino acid (aa) identity (1, 2). All contain fifteen LRRs flanked by cysteine-rich regions and three C-type Ig-like domains within their extracellular domains (ECD) (1, 2). LRIG1 shows the highest expression in liver, brain, stomach, small intestine and skeletal muscle (2). Expression is prominent in certain epithelia and subsets of glial cells (1, 2). Within the cell, LRIG1 is expressed in the perinuclear region as well as on the surface. Mouse LRIG1 is synthesized with a 37 aa signal sequence, a 759 aa ECD, a 21 aa transmembrane sequence and a 295 aa intracellular region that binds the ubiquitin ligase, c-Cbl (3). LRIG1 binds the EGF receptor (ErbB1) or neuregulin receptors (ErbB2, 3 and 4) via either its LRR or Ig-like domains and promotes ubiquitination, internalization and destruction of these receptors (3, 4). Since LRIG1 modulates growth factor receptor expression, there is an inverse relationship between LRIG1 expression and proliferative capacity. Genetic disruption of mouse LRIG1 results in a psoriasis-like epidermal hyperplasia on the tail and facial area, which is consistent with downregulation of LRIG1 in human psoriatic lesions (5). High ratios of EGF R to LRIG1 in human renal cell carcinomas correlate with poor survival (6). In skin squamous cell carcinomas, high LRIG1 expression correlates with a more differentiated state and a survival benefit (7). Mouse LRIG1 ECD shows 90%, 93%, 90% and 87% aa identity with human, rat, bovine and canine LRIG1 ECD, respectively.

Long Name

Leucine-rich Repeats and Immunoglobulin-like Domains 1

Entrez Gene IDs

26018 (Human); 16206 (Mouse); 312574 (Rat)

Alternate Names

D6Bwg0781e; Img; LIG1; LIG-1; LRIG1